Merck is ending Zinplava sales in Europe after stopping them in the United States in December 2024. Losing another market for the drug is a business setback, though the story gives no sales figures to show its size.
The lost sales opportunity now includes Europe, after Merck stopped selling Zinplava in the United States in December 2024. That is a setback for Merck, though the story gives no sales figures to show how much the drug contributed.
Follow Merck & Co Inc. (MRK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRK